PCS
UROV

Personal CFO Solutions’s Urovant Sciences Ltd. UROV Stock Holding History

Personal CFO Solutions’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,388
Closed – – 413
2020
Q3 		$0 Hold
34,388
– – ﹤0.01% 355
2020
Q2 		$338K Buy
+34,388
New +$330K 0.1% 190

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Personal CFO Solutions's UROV Position: Q4 2020 in Review

Personal CFO Solutions sold out of Urovant Sciences Ltd. (UROV) in Q4 2020, closing a stake of 34,388 shares.

Personal CFO Solutions first reported a position in UROV in Q2 2020 and held it in 2 quarters. The position peaked at $338K in Q2 2020. 41 funds tracked by Wall St. Rank hold UROV as of Q4 2020.

  • Personal CFO Solutions reported no remaining Urovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Personal CFO Solutions sold 34,388 Urovant Sciences Ltd. shares in Q4 2020.
  • Personal CFO Solutions first reported a position in Urovant Sciences Ltd. in Q2 2020 and held it in 2 quarters.
  • Personal CFO Solutions's Urovant Sciences Ltd. position peaked at $338K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2020.

Based on Personal CFO Solutions's 13F filing for Q4 2020, filed 9 Feb 2021.